Author(s): Ammar A. Razzak Mahmood Kubba, Wurood A. Shihab, Nada N Al-Shawi

Email(s): Kubbaammar1963@gmail.com

DOI: 10.5958/0974-360X.2020.00591.0   

Address: Ammar A. Razzak Mahmood Kubba1*, Wurood A. Shihab2, Nada N Al-Shawi3
1Dept. of Pharmaceutical Chemistry, College of Pharmacy-University of Baghdad, Bab-Al-Mouadam, 10001, Baghdad-Iraq.
2Dept of Pharmaceutical Chemistry, University of Ashur-Baghdad, Al-Wazirya, Iraq.
3Dept of Pharmacology and Toxicology, College of Pharmacy-University of Baghdad, Bab-Al-Mouadam, 10001, Baghdad-Iraq.
*Corresponding Author

Published In:   Volume - 13,      Issue - 7,     Year - 2020


ABSTRACT:
A series of three 5-(4-aminophenyl)-4-substituted phenyl- 2,4 dihydro-3H-1,2,4-triazole-3-thione analogs were designed, synthesized and investigated for anti-proliferative activity using in-silico and in vitro studies. The synthesis started by reaction of ethyl-4-aminobenzoate with hydrazine hydrate in absolute ethanol, to yield intermediate 1, then cyclization of intermediate 1 was performed by addition of carbon disulfide (CS2) in the presence of anhydrous potassium hydroxide (KOH) in absolute ethanol to afford the parent nucleus, 5-(4-aminophenyl)-1,3,4-oxadiazole-2-thione (2), which underwent nucleophilic substitution reaction with three different aromatic amines, using pyridinium trifluoroacetate (PTFA) as a catalyst, to yield three moieties of 1,2,4- triazole derivatives 3, 4 and 5, respectively. They were analyzed utilizing FTIR and 1HNMR spectroscopy, and their physical properties were measured. The target compounds (3, 4, and 5) were investigated for their plausible anti-proliferative effect against Epidermal Growth Factor Receptor (EGFR) drug target using molecular modeling, docking and simulations studies. As per docking results, compound 5 has shown the best inhibitory potential by showing binding energy of - 6.38Kcal/mol. Compounds 3 and 4 were shown to be the second and third best with estimated binding free energies of -6.12kcal/mol, and, followed by -6.02kcal/mol, respectively. Several interesting molecular level interactions have been revealed during the molecular dynamic (MD) simulation of compound 5 with EGFR drug target. To validate these insilico predictions, the three compounds were tested on two human cell lines, HeLa, and MCF-7 cancer cell lines, to check their antiproliferative activity. The cytotoxicity for compound 5 in this series was higher with IC50 value measured as 22.83µg/ml and 20.14 µg/ml for HeLa and MCF-7 cell lines, respectively in comparison with compound 3 (IC50 value was 36.71 µg/ml, 35.44 µg/ml), and compound 4, which demonstrated the lowest activity against both cell lines with IC50 value of 47.19 µg/ml, 45.82 µg/ml, HeLa and MCF-7 cell lines respectively. Invitro studies output was in agreement with insilico predictions that compound 5 among the tested compounds has the best potential to act as an anti-proliferative agent.


Cite this article:
Ammar A. Razzak Mahmood Kubba, Wurood A. Shihab, Nada N Al-Shawi. Insilico and in vitro Approach for Design, Synthesis, and Anti-proliferative Activity of Novel Derivatives of 5-(4-Aminophenyl)-4-Substituted Phenyl-2, 4-Dihydro-3H-1, 2, 4-Triazole-3-Thione. Research J. Pharm. and Tech. 2020; 13(7): 3329-3339. doi: 10.5958/0974-360X.2020.00591.0

Cite(Electronic):
Ammar A. Razzak Mahmood Kubba, Wurood A. Shihab, Nada N Al-Shawi. Insilico and in vitro Approach for Design, Synthesis, and Anti-proliferative Activity of Novel Derivatives of 5-(4-Aminophenyl)-4-Substituted Phenyl-2, 4-Dihydro-3H-1, 2, 4-Triazole-3-Thione. Research J. Pharm. and Tech. 2020; 13(7): 3329-3339. doi: 10.5958/0974-360X.2020.00591.0   Available on: https://rjptonline.org/AbstractView.aspx?PID=2020-13-7-51


REFERENCES:
1. Kiran Singh, D. P. Singh. Manjeet Singh Barwa. Parikshit Tyagi & Yasmin Mirza, Some bivalent metal complexes of Schiff bases containing N and S donor atoms, J. Enzy. Inhib. Med. Chem., 2006; 21(6): 749 -755. 
2. Afaf H. El-Masry, H. H. Fahmy and S. H. Ali Abdel wahed, Synthesis and antimicrobial activity of some new Benzimidazole derivatives, Molecules, 2000; 5(12): 1429-1438.
3. Jianming Xu a, Yongbing Cao b, 1, Jun Zhang c; Shichong Yu a, Yan Zou a, Xiaoyun Chai a, Qiuye Wu a, Dazhi Zhang a, Yuanying Jiang b; Qingyan Sun., Design, synthesis and antifungal activities of novel 1,2,4-triazole derivatives, Europ. J. Med .Chem., 2011;46 (7): 3142-3148. 
4. Cheng-Xia Tan, a Yan-Xia Shi, c Jian-Quan Weng, a Xing-Hai Liu, a Wei-Guang Zhao,b, and Bao-Ju Lic, Synthesis and antifungal activity of novel 1,2,4-triazole derivatives containing 1,2,3-thiadiazole moiety, J. Heterocyc. Chem., 2014; 51(3): 690-694. 
5. Kamboj VK, Verma PK, Dhanda A, Ranjan S., 1,2,4-Triazole derivatives as a potential scaffold for anticonvulsant activity, Cent Nerv Syst Agent. Med. Chem., 2015; 15(1): 17-22. 
6. Hany A.M. El-Sherief, Bahaa G.M. Youssif, Syed Nasir Abbas Bukhari, Mohamed Abdel-Aziz, Hamdy M. Abdel-Rahman, Novel 1,2,4-triazole derivatives as potential anticancer agents: Design, synthesis, molecular docking, and mechanistic studies, Bioorg. Chem., 2018; 76: 314-325. 
7. Romeo Romagnoli, Pier Giovanni Baraldi, Olga Cruz-Lopez, Carlota Lopez Cara, Maria Dora Carrion, Andrea Brancale, Ernest Hamel, Longchuan Chen, Roberta Bortolozzi, Giuseppe Basso, and Giampietro Viola, Synthesis and antitumor activity of 1,5-disubstituted 1,2,4-triazoles as cis-restricted combretastatin analogs, J. Med. Chem., 2010; 53(10): 4248–4258. 
8. Rajeev Kharb, Prabodh Chander Sharma, and Mohammed Shahar Yar, Pharmacological significance of triazole scaffold, J. Enz. Inhib. Med. Chem., 2011;26(1): 1–21.
9. Guogang Tu, Yugang Yan, Xueying Chen, Qiaoli Lv, Jiaqi Wang, Shaohua Li, Synthesis and antiproliferative assay of 1,3,4-oxadiazole and 1,2,4-triazole derivatives in cancer cell, Drug. Discov. Ther., 2013;7(2): 58-65.
10. Firas Abdullah Hassan, Khalid Waleed Younus, and Alaa Hussain AL-Qaisi, Antitumoral effect of 1, 2, 4-triazole derivatives on prostate carcinoma (DU145), human liver carcinoma (HEPG2), and human breast cancer (MCF7) cell lines, Aust. J. Basic & Appl. Sci., 2013;7(2): 133-140.
11. Marius Mioc, Codruta Soica, Vasile Bercean, Sorin Avram, Mihaela Balan‑Porcarasu, Dorina Coricovac, Roxana Ghiulai, Delia Muntean, Florina Andrica, Cristina Dehelean, Demetrios A. Spandido s, Aristides M. Tsat sakis and Ludovic Kurunczi, Design, synthesis and pharmaco-toxicological assessment of 5-mercapto-1,2,4-triazole derivatives with antibacterial and antiproliferative activity, Int. J. Oncol., 2017; 50: 1175-1183.
12. Zhang Q, Peng Y, Wang XI, Keeman SM, Aurora S, Welsh WJ. Highly potent triazole-based tubulin polymerization inhibitors, J. Med. Chem., 2007;50(40): 749–754.
13. Seema-Maria Nathwani, Lnda Hughes, Lisa M. Greene, MiriamCarr, Niamh M. O’boyle, Susan Mcdonnell, Mary J. Meegan, and Daniela M. Zisterer, Novel cis-restricted β-lactam combretastatin A-4 analogs display anti-vascular and anti-metastatic properties in vitro, Oncol. Rep., 2013; 29(2): 585-594.
14. Y. P. Quan, L. P.Cheng, T. C. Wang, W. Pang, F. H. Wu, and J. W. Huang, Molecular modeling study, synthesis and biological evaluation of Combretastatin A-4 analogs as anticancer agents and tubulin inhibitors, Med. Chem. Commun., 2018;9(2): 316-327.
15. D’Amato R, Lin C, Flynn E, Folkman J, Hamel E., 2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site, Proc. Natl. Acad. Sci., USA, 1994; 91(9): 3964-3968.
16. Kuznetsov G, TenDyke K, Towle M, Cheng H, Liu J, Marsh J, Schiller S, Spyvee M, Yang H, Seletsky B, Shaffer C, Marceau V, Yao Y, Suh E, Campagna S, Fang F, Kowalczyk J, Littlefield B., Tubulin-based antimitotic mechanism of E7974, a novel analogue of the marine sponge natural product hemiasterlin, Mol. Cancer Ther., 2009;8(10): 2852-2860.
17. Pettit, G. R.; Singh, S. B.; Boyd, M. R.; Hamel, E.; Pettit, R. K.; Schmidt, J. M.; Hogan, F., Antineoplastic Agents. 291. Isolation and synthesis of Combretastatin A-4, A-5, and A-6. J. Med. Chem., 1995;38 (10): 1666-1672.
18. Hori, K; Saito, S; Nihei, Y; Suzuki, M, Sato, Y., “Antitumor effects due to irreversible stoppage of tumor tissue blood flow: evaluation of a novel combretastatin A-4 derivative, AC7700”. Jpn. J. Cancer Res., 1999; 90 (9):1026–1038.
19. Hori, K; Saito, S; Kubota, K., “A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs”, Br. J. Cancer, 2002; 86 (10): 1604–1614.
20. Aykul S, Martinez-Hackert E., Determination of half-maximal inhibitory concentration using biosensor-based protein interaction analysis, Anal. Biochem ., 2016;508: 97-103.
21. Emad Ghanem & Sahar Al-Hariri, Synthesis and powder X-ray diffraction of new Schiff-base liquid crystal. Liq. Cryst. Today, 2013; 22(4):76-81.
22. Schrödinger Release 2018-4: Maestro, Schrödinger, LLC, New York, NY, 2018.
23. Dassault Systèmes BIOVIA, Discovery studio, v4.0, San Diego: Dassault Systèmes, 2016.24. Morris, G. M., Huey, R., Lindstrom, W., Sanner, M. F., Belew, R. K., Goodsell, D. S. and Olson, A. J., Autodock4 and AutoDockTools4: automated docking with selective receptor flexibility, J. Comput. Chem., 2009;16: 2785-2791.
24. Desmond Molecular Dynamics System, D. E. Shaw Research, New York, NY, 2018.
25. Jennifer Stamos, Mark X. Sliwkowski, and Charles Eigenbrot, Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline Inhibitor, J.Biol.Chem., 2002 ;227(48): 46265-46272.
26. H.M. Berman, J. Westbrook, Z. Feng, G. Gilliland, T.N. Bhat, H. Weissig, I.N. Shindyalov, P.E. Bourne., The Protein Data Bank, Nucleic Acids Res., 2000 ;28: 235-242.
27. Brooks BR, Bruccoleri RE, Olafson BD, States DJ, Swaminathan S, Karplus M., “CHARMM: A program for macromolecular energy, minimization, and dynamics calculations”. J. Comput. Chem., 1983; 4 (2): 187–217.
28. MacKerell, A.D., Jr.; Brooks, B.; Brooks, C. L., III; Nilsson, L.; Roux, B., Won, Y.; Karplus, M., “CHARMM: The Energy function and its parameterization with an overview of the program”. In Schleyer, P.v.R.; et al. The Encyclopedia of Computational Chemistry. 1. Chichester: John Wiley & Sons. 1998, p. 271–277.
29. Brooks, Bernard R., C.L. Brooks, III, A.D. MacKerell, Jr., L. Nilsson, R.J. Petrella, B. Roux, Y. Won, G. Archontis et al., “CHARMM: the biomolecular simulation program,” J. Comput. Chem., 2009; 30(10): 1545-1614.
30. Mark, Pekka, and Lennart Nilsson. “Structure and dynamics of the TIP3P, SPC, and SPC/E water models at 298 K,” J. Phys. Chem., 2001;105(43): 9954-9960.
31. Reddy SV, Reddy KT, Kumari VV, Basha SH., “Molecular docking and dynamic simulation studies evidenced plausible immunotherapeutic anticancer property by withaferin A targeting indoleamine 2, 3-dioxygenase,” J. Biomol. Struct. Dyn., 2015; 33(12): 2695-2709.
32. Rather MA, Basha SH, Sharma N, Nandanapawar P, Badhe M, P GB, Chaudhari A, Sundaray JK, Sharma R., “Characterization, molecular docking, dynamics simulation and metadynamics of kisspeptin receptor with kisspeptin, Int. J. Biol. Macromol., 2017;101: 241-253.
33. Samad, Firoz Abdul, Bandar A.Suliman, Sayed Hussain Basha, Thamilarasan Manivasagam, Mustafa Mohamed Essa, “A comprehensive In Silico analysis on the structural and functional impact of SNPs in the congenital heart defects associated with NKX2-5 gene A molecular dynamic simulation approach,” PloS one. 2016; 11(5):1-16
34. Andersen, Hans C., “Molecular dynamics simulations at constant pressure and/or temperature,” J. Chem. Phys., 1980; 72(4): 2384-2393.
35. Evans, Denis J., and Brad Lee Holian. “The nose hoover thermostat,” J. Chem. Phys., 1985;83(8): 4069-4074.
36. Sulaiman GM, Jabir MS, Hameed AH., Nanoscale modification of chrysin for improved of therapeutic efficiency and cytotoxicity Artif Cells, Nanomed. Biotechnol., 2018;31: 1-13. 
37. Al-Shammari AM, Salman MI, Saihood YD, Yaseen NY, Raed K, Shaker HK, Ahmed A, Khalid A, Duiach A., In vitro synergistic enhancement of  ewcastle disease virus to 5-fluorouracil cytotoxicity against tumor cells. Biomedicines, 2016;4(3): 1-10.
38. Senthilraja P, Kathiresan K., In vitro cytotoxicity MTT assay in Vero, HepG2, and MCF -7 cell lines study of Marine Yeast. J. Appl. Pharm. Sci., 2015; 5 (03): 080-084. 
39. Jabir M.S, Sulaiman G.M, Taqi Z.J., Li D., Iraqi propolis increases degradation of IL-1β and NLRC4 by autophagy following Pseudomonas aeruginosa infection. Microbes. Infect., 2018;20(2): 89-100
40. Souad A. Elmetwally, Khaled F. Saied, Ibrahim H. Eissa, Eslam B. Elkaeed, Design, synthesis and anticancer evaluation of thieno[2,3-d]pyrimidine derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers, Bioor. Chem., 2019; DOI:https:// doi.org/10.1016/j.bioorg.2019.102944. 
41. Rather, Mohd Ashraf, Basha, Syed Hussain, Bhat, Irfan Ahmad, Sharma, Niti,” Characterization, molecular docking, dynamics simulation and metadynamics of kisspeptin receptor with kisspeptin,” In.t J. Biol. Macromol., 2017;101: 241-253.
42. Herlina Rasyid, Ria Armunanto, Bambang Purwono, Molecular docking analysis on epidermal growth factor receptor Wild Type (EGFRwt) with quinazoline derivative compounds as tyrosine kinase inhibitors, Int. J. Appl. Sci. Techno., 2017;10(4): 293-299.

Recomonded Articles:

Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal.... Read more >>>

RNI: CHHENG00387/33/1/2008-TC                     
DOI: 10.5958/0974-360X 

0.38
2018CiteScore
 
56th percentile
Powered by  Scopus


SCImago Journal & Country Rank


Recent Articles




Tags


Not Available